Three Swiss firms have been charged with insider trading in the United States following Lonza Group’s recent $1.2 billion (SFr980 million) acquisition of Arch Chemicals.
This content was published on
1 minute
swissinfo.ch and agencies
The US Securities and Exchange Commission (SEC) said in a statement on Monday that a New York federal judge had granted its request for emergency relief against the companies and froze assets belonging to them pending an injunction hearing.
According to the SEC, the three Swiss-based companies – Compania International Financiera, Coudree Capital Gestion and Chartwell Asset Management Services – purchased more than a million common shares of Arch in the days leading up to the Lonza deal last week.
“Immediately after the acquisition announcement on July 11, the firms began selling the recently-purchased shares of Arch common stock for millions of dollars in profits,” the SEC said.
The SEC said it believed the companies were in possession of non-public information about Lonza’s proposed acquisition at the time the shares were purchased.
Ira Lee Sorkin, an attorney representing Compania International Financiera and Coudree Capital Gestion, said the two firms are contesting the SEC’s allegations.
A preliminary injunction hearing is scheduled for July 25.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Lonza buys Arch Chemicals for $1.2 billion
This content was published on
The takeover will create the world’s biggest microbial-control business. Lonza, the world’s biggest maker of drug ingredients, said on Monday it would pay $47.20 a share, 12 per cent higher than the closing price on Friday. Shares of Connecticut-based Arch surged 11 per cent on Friday, the most in 14 months. Arch’s products are used…
This content was published on
The private group recently moved its headquarters and tax residence from Southampton, Britain, to the village on the shores of Lake Geneva to benefit from its central European location and to save on tax bills. swissinfo.ch went to find out more. “Clearly we’ve grown very quickly and having developed a global business we needed a…
This content was published on
Jimenez, in his own words, doesn’t even notice that Novartis is Swiss. In the era of multinational corporate giants, the management code appears to be universal and nationality irrelevant. But how far have Swiss-based multinationals drifted from their roots? In a global marketplace is corporate culture the only culture that counts? Success brings expansion, and…
This content was published on
Profit rose to SFr222 million ($178 million) from SFr188 million in 2005, while turnover was up by 15.6 per cent to SFr2.91 billion. Lonza said it expected sales growth of eight to 12 per cent over the next few years and operating profit growth in the mid to high teens. The company has repositioned itself…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.